首页> 外文期刊>American journal of therapeutics >Successful Treatment of Refractory Idiopathic Hypereosinophilic Syndrome With Etoposide
【24h】

Successful Treatment of Refractory Idiopathic Hypereosinophilic Syndrome With Etoposide

机译:依托泊苷成功治疗难治性特发性嗜酸性粒细胞增多综合征

获取原文
获取原文并翻译 | 示例
           

摘要

Idiopathic hypereosinophilic syndrome represents a heterogenous group of leukoproliferative disorders with hypereosinophilia of an unknown etiology resulting in multiorgan dysfunction. The disease can involve any organ but commonly involves heart, nervous system, skin, and gastrointestinal system. Steroids and chemotherapy agents remain the mainstay of the treatment to suppress organ damage and eradicate eosinophilia. We are presenting an interesting patient of idiopathic hypereosinophilic syndrome with cardiac involvement who was refractory to many chemotherapeutic drugs including imatinib but had an excellent response to etoposide. Although the mechanism by which etoposide works in this disease is not well understood, it has been tried in the past with success. The patient is off therapy for the past 24 months with stable eosinophil count.
机译:特发性嗜酸性粒细胞增多综合症代表异源性白细胞增生性疾病,其病因学未知,导致多器官功能障碍。该疾病可累及任何器官,但通常累及心脏,神经系统,皮肤和胃肠系统。类固醇和化疗药物仍然是抑制器官损伤和根除嗜酸性粒细胞增多症的主要治疗手段。我们正在介绍一名有趣的患有心脏受累的特发性高嗜酸性粒细胞综合征患者,该患者对包括伊马替尼在内的许多化学治疗药物均无效,但对依托泊苷的反应良好。尽管依托泊苷在该疾病中起作用的机制尚不十分清楚,但过去已成功尝试。该患者在过去24个月内停止治疗,且嗜酸性粒细胞计数稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号